211 related articles for article (PubMed ID: 22954004)
1. GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.
Matthaei H; Wu J; Dal Molin M; Debeljak M; Lingohr P; Katabi N; Klimstra DS; Adsay NV; Eshleman JR; Schulick RD; Kinzler KW; Vogelstein B; Hruban RH; Maitra A
HPB (Oxford); 2012 Oct; 14(10):677-83. PubMed ID: 22954004
[TBL] [Abstract][Full Text] [Related]
2. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
Sasaki M; Matsubara T; Nitta T; Sato Y; Nakanuma Y
PLoS One; 2013; 8(12):e81706. PubMed ID: 24312577
[TBL] [Abstract][Full Text] [Related]
3. GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct.
Tsai JH; Yuan RH; Chen YL; Liau JY; Jeng YM
Am J Surg Pathol; 2013 Dec; 37(12):1862-70. PubMed ID: 24061513
[TBL] [Abstract][Full Text] [Related]
4. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
[TBL] [Abstract][Full Text] [Related]
5. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
6. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
[TBL] [Abstract][Full Text] [Related]
7. GNAS and KRAS mutational analyses of intraductal papillary neoplasms of the pancreas and bile duct developing in the same individual: A case report.
Date K; Ohtsuka T; Fujimoto T; Gotoh Y; Nakashima Y; Kimura H; Matsunaga T; Mori Y; Mochidome N; Miyazaki T; Oda Y; Tanaka M; Nakamura M
Pancreatology; 2015; 15(6):713-6. PubMed ID: 26506885
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
[TBL] [Abstract][Full Text] [Related]
9. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?
Rocha FG; Lee H; Katabi N; DeMatteo RP; Fong Y; D'Angelica MI; Allen PJ; Klimstra DS; Jarnagin WR
Hepatology; 2012 Oct; 56(4):1352-60. PubMed ID: 22504729
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
[TBL] [Abstract][Full Text] [Related]
12. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
13. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.
Aoki Y; Mizuma M; Hata T; Aoki T; Omori Y; Ono Y; Mizukami Y; Unno M; Furukawa T
J Pathol; 2020 May; 251(1):38-48. PubMed ID: 32100878
[TBL] [Abstract][Full Text] [Related]
14. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
15. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
17. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
Wu J; Matthaei H; Maitra A; Dal Molin M; Wood LD; Eshleman JR; Goggins M; Canto MI; Schulick RD; Edil BH; Wolfgang CL; Klein AP; Diaz LA; Allen PJ; Schmidt CM; Kinzler KW; Papadopoulos N; Hruban RH; Vogelstein B
Sci Transl Med; 2011 Jul; 3(92):92ra66. PubMed ID: 21775669
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutation and immunohistochemical profile in intraductal papillary neoplasm of the intrahepatic bile ducts.
Xian ZH; Qin C; Cong WM
Pathol Res Pract; 2018 Jan; 214(1):105-111. PubMed ID: 29103773
[TBL] [Abstract][Full Text] [Related]
20. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
